Tele: 561.316.3330
Breaking Medical Device News

Thursday, September 23, 2021
HomeBAXTERData on Telehealth’s Role in Improving Peritoneal Dialysis Patient Care at ERA-EDTA 2017

Data on Telehealth’s Role in Improving Peritoneal Dialysis Patient Care at ERA-EDTA 2017

  • Physicians using SHARESOURCE remote patient management – a telehealth platform – have more accurate and timely visibility to their patients’ home therapy adherence
  • Remote patient management allows for earlier intervention in response to PD patient clinical issues
  • Nurses managing patients via remote patient management reported a 35 percent increase in time available to perform proactive patient-related tasks

Baxter International Inc. (NYSE: BAX) presented new data demonstrating the abilities of its SHARESOURCE remote patient management technology to improve peritoneal dialysis (PD) patient care and increase dialysis clinic efficiencies. The findings were shared at the 54th Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA), June 3-6.

Data show SHARESOURCE, a unique two-way, cloud-based technology platform that comes with the HOMECHOICE CLARIA automated PD (APD) system, is offering healthcare providers more accurate and timely visibility to their patients’ therapy adherence, allowing earlier discovery and intervention for clinical issues (Abstract #MP557). Additional data show the technology is associated with nurses gaining as much as 35 percent more time to perform proactive patient-related work (Abstract #SP508).

“Baxter’s SHARESOURCE remote patient management system was designed to support patients’ access to PD, with the confidence to perform home therapy knowing their healthcare providers are remotely managing their care,” said James Sloand, M.D., senior medical director, Baxter. “New data show the technology can help healthcare providers achieve this goal because they have timely access to accurate patient therapy adherence data, allowing them to address pertinent clinical issues earlier.”

The discrepancy between actual APD treatment time compared with prescribed treatment time (Abstract #MP557) was evaluated, because non-adherence (missing >10% of prescribed PD therapy (≥four treatments)) is associated with poor clinical outcomes, including, but not limited to peritonitis1,2 . The study included 399 European APD patients using remote patient management over a one-year period, and showed an average of 30 percent of patients were non-adherent in the first month on therapy.

An additional study determined remote patient management is associated with a change in the PD nursing paradigm, providing nurses more time to focus on proactive clinical management and better prioritize patients, and potentially support earlier interventions (Abstract #SP508). The observational study included more than 36 hours of monitoring the work routines of three PD nurses, each working at a different hospital. The nurses’ work routines were observed prior to the use of remote patient management and after the technology was established at their facilities.

Keeping Patients on PD Therapy

Preliminary results on early PD attrition from the PD Outcomes and Practice Patterns Study (PDOPPS) – a Baxter co-sponsored research effort looking at treatment and outcomes across seven countries – showed about 10 percent of PD patients drop out within 120 days (Abstract #MO061). Overall, catheter-related complications were the most frequent (21 percent) reason for patients to transfer to hemodialysis. Further patient recruitment and longer study follow up will allow PDOPPS to better understand the causes and develop recommendations to help patients stay on therapy longer.

Baxter’s SHARESOURCE has helped healthcare providers manage more than 700,000 PD patients’ home therapy sessions across the company’s HOMECHOICE CLARIA and AMIA APD systems. HOMECHOICE CLARIA with SHARESOURCE is available in select European, Asian and Latin American countries. SHARESOURCE is available with AMIA in the United States and Canada.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Matthew Cranfill New ExtriCARE USA Director Of Clinical Services

"Matt's impressive experience and skillset easily made him our top pick," said Peter Mason, President of ExtriCARE USA.

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

By using this website you agree to accept Medical Device News Magazine Privacy Policy